Valeant Pharmaceuticals Announces License Of ACZONE Gel 5% In Canada

Valeant Pharmaceuticals International, Inc. VRX today announced that its subsidiary, Biovail Laboratories International SRL, has entered into an agreement to license the Canadian rights to ACZONE Gel 5%, a topical formulation of dapsone used in the treatment of acne vulgaris, from Allergan. Allergan will receive from BLS a CA$500,000 upfront payment to be followed by subsequent additional payments based on net sales.